Doxazosin mysylate GITS — Competitive Intelligence Brief

Doxazosin mysylate GITS (Doxazosin mysylate GITS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Cardiovascular; Urology.

marketed Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Cardiovascular; Urology Small molecule

Target snapshot

Doxazosin mysylate GITS (Doxazosin mysylate GITS) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doxazosin mysylate GITS TARGET	Doxazosin mysylate GITS	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Pseudoephedrine/Paracetamol	Pseudoephedrine/Paracetamol	McNeil AB	marketed	Decongestant/analgesic combination	Alpha-1 adrenergic receptor (pseudoephedrine); COX inhibition (paracetamol)
Epinephrine Injection	Epinephrine Injection	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	marketed	Catecholamine; alpha and beta adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Levobupivacaine with epinephrine	Levobupivacaine with epinephrine	Pontificia Universidad Catolica de Chile	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Continuous infusion of Norepinephrine	Continuous infusion of Norepinephrine	Hassan II University	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor
Visine® for Contacts®	Visine® for Contacts®	Merck Sharp & Dohme LLC	marketed	Ophthalmic decongestant	Alpha-1 adrenergic receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

1. Brian J Lipworth · 1 drug in this class
2. CHU de Quebec-Universite Laval · 1 drug in this class
3. Eli Lilly and Company · 1 drug in this class
4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
5. Hospital Authority, Hong Kong · 1 drug in this class
6. Japan Heart Foundation · 1 drug in this class
7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class